Research Report Initiation on Generic Drugs Makers Stocks -- Ironwood Pharma, The Medicines, Carbylan Therapeutics, and Pacira Pharma

Aug 24, 2016, 08:00 ET from Chelmsford Park SA

NEW YORK, August 24, 2016 /PRNewswire/ --

The global Generic Drugs market is forecasted to grow at a CAGR of 10.53% over the period of 2016 to 2020, according to the 'Global Generic Drugs Market 2016-2020' report released in June 2016. Today, assesses the following companies stocks to see if they are poised for higher returns: Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), The Medicines Co. (NASDAQ: MDCO), Carbylan Therapeutics Inc. (NASDAQ: CBYL), and Pacira Pharmaceuticals Inc. (NASDAQ: PCRX). Learn more about these stocks by downloading their free report at:

Ironwood Pharma  

On Tuesday, shares in Cambridge, Massachusetts headquartered Ironwood Pharmaceuticals Inc. recorded a trading volume of 969,790 shares. The stock ended the day at $13.97, climbing 1.23%. The Company's shares have gained 15.84% over the previous three months and 20.53% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.88% and 21.88%, respectively. Furthermore, shares of Ironwood Pharmaceuticals, which engages in the research, development, and commercialization of human therapeutic products, have a Relative Strength Index (RSI) of 59.41.

On August 4th, 2016, Ironwood Pharmaceuticals reported that collaborative arrangements revenue was $54.4 million in Q2 2016, compared to $27.7 million in Q2 2015. Revenue primarily consisted of $48.3 million in revenue associated with Ironwood's share of the net profits from the sales of LINZESS in the US, compared to $24.3 million in Q2 2015. The company's GAAP net loss was $21.7 million, or $0.15 per share, in Q2 2016, compared to $48.0 million, or $0.34 per share, in Q2 2015. The free research report on IRWD is available at:

The Medicines  

Parsippany, New Jersey-based The Medicines Co.'s stock finished yesterday's session 2.94% higher at $39.58 with a total trading volume of 1.05 million shares. The Company's shares have gained 11.87% in the last one month, 6.14% over the previous three months, and 6.00% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 9.61% and 11.33%, respectively. Furthermore, shares of The Medicines, which provides medicines for patients in acute and intensive care hospitals worldwide, have an RSI of 69.11.

On July 27th, 2016, The Medicines reported that worldwide net revenue was $54.7 million in Q2 2016 compared to $74.5 million in Q2 2015. The sale of the Company's non-core cardiovascular products resulted in a gain of $288.3 million, which was recorded in Q2 2016. Net income from continuing operations in Q2 2016 was $181.8 million, or $2.51 per share. The complimentary report on MDCO can be downloaded at:

Carbylan Therapeutics  

At the closing bell on Tuesday, shares in Palo Alto, California headquartered Carbylan Therapeutics Inc. rose 1.05%, ending the day at $0.58. The stock recorded a trading volume of 3.01 million shares, which are above its three months average volume of 975,750 shares. The Company's shares are trading 9.53% below their 50-day moving average. Moreover, shares of Carbylan Therapeutics, which focuses on the development and commercialization of novel and proprietary combination therapies, have an RSI of 51.90.

As per the form 10-Q filed with the SEC on August 12th, 2016, Carbylan Therapeutics reported net loss of $7.35 million, or $(0.28) per diluted share, for the quarter ended on June 30th, 2016, as compared to net loss of $9.01 million, or $(0.40) per diluted share, for the quarter ended on June 30th, 2015. As of June 30th, 2016, the company had cash and cash equivalents worth $36.82 million compared to cash and cash equivalents of $53.72 million as of December 31st, 2015. Visit us today and download our complete research report on CBYL for free at:

Pacira Pharma  

Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc.'s stock ended the day 1.05% higher at $43.40 with a total trading volume of 351,286 shares. The Company's shares have gained 15.24% in the last month. The stock is trading 10.87% above its 50-day moving average. Additionally, shares of Pacira Pharmaceuticals, which develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 56.46.

On August 4th, 2016, Pacira Pharmaceuticals reported that total revenues were $69.6 million in Q2 2016, an 18% increase over the $59.1 million reported for Q2 2015. The company's GAAP net loss was $8.0 million, or $(0.21) per share (basic and diluted), in Q2 2016 compared to GAAP net income of less than $0.1 million, or $0.00 per share (basic and diluted), in Q2 2015. Get free access to your technical report on PCRX at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA